CTYHealthcare · Biotechnology

CTY Stock Forecast: City Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026

$16

−14.04% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 4 Nov 2026 — in the weakest quartile.

Market cap

$960.8M

Ticker Nerd rank

0/ 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−24.2%

From high

−26.7%

From low

0.0%

$16

$22

Range since 16 Oct 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

CTY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores City Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026

0/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Growth

Accruals

Value

Quality

Volatility

Momentum

Issuance

Size (46): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTY, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CTY appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Estimates

CTY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

City Therapeutics, Inc. (CTY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 67.0×
Price / book: —
EV / EBITDA: −2.9×

Growth & margins

Revenue growth (YoY): 14.0%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −804.2%
Net margin: 0.0%

Returns & dividend

Return on equity: —
Return on assets: —
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

City Therapeutics, Inc. (CTY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

City Therapeutics, Inc. has a market value of $960.8M and an enterprise value of $244.4M.
Shares outstanding: 50.3M.
Forward dividend yield: 0.00%.
City Therapeutics, Inc. employs 75 people.

market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

CTY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CTYCity Therapeutics, Inc.	$960.8M	0
AKTSAktis Oncology, Inc.	$840.2M	2
ALMSAlumis, Inc.	$833.2M	40
MGTXMeiraGTx Holdings Plc	$871.9M	78
ANNXAnnexon, Inc.	$820.9M	37
ARDXArdelyx, Inc.	$819.8M	55
CRVSCorvus Pharmaceuticals, Inc.	$885.4M	61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own City Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTY news & analysis

Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting

GlobeNewsWire · 4 Nov 2026positive

City Therapeutics said data from its CITY-FXI and CITY-TFR2 programs will be presented at the 68th American Society of Hematology Annual Meeting, scheduled for December 12–15, 2026, in New Orleans. The headline says CITY-FXI Phase 1 data were selected for an oral presentation.

Why it matters — The presentations will provide CTY watchers with an opportunity to follow data from two of the company’s RNAi programs.

City Therapeutics to Present at Upcoming November Investor Conferences

GlobeNewsWire · 3 Nov 2026neutral

City Therapeutics announced that its management will participate in investor conferences in November. The company is a clinical-stage biotechnology company developing RNA interference therapeutics.

Why it matters — The announcement gives CTY watchers information about upcoming opportunities to hear from company management.

Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere

Barrons · 24 Oct 2026neutral

Several biotech companies are going public while investors await Anthropic’s official IPO filing, and the biotech IPOs are reportedly doing well.

Why it matters — The item highlights activity in biotech IPOs, a sector context relevant to watchers of City Therapeutics.

FAQ

Frequently asked questions about CTY stock

How does Ticker Nerd's model rank CTY?

As at 4 Nov 2026, City Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (46 of 100).

What is the CTY stock forecast for 2030?

No analyst covering City Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTY are extrapolating price history, which says nothing about the business.

What does City Therapeutics, Inc. do?

City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics designed to silence disease-related genes at the molecular level.

What is the latest news on CTY?

The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting". City Therapeutics said data from its CITY-FXI and CITY-TFR2 programs will be presented at the 68th American Society of Hematology Annual Meeting, scheduled for December 12–15, 2026, in New Orleans. The headline says CITY-FXI Phase 1 data were selected for an oral presentation.

Company

About City Therapeutics, Inc.

City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics designed to silence disease-related genes at the molecular level. Its platform engineers small interfering RNA (siRNA) trigger molecules and combines them with tissue-selective targeting technologies to improve delivery beyond the liver, including to ocular, central nervous system, and adipose tissues. The company applies genetics-driven target selection and proprietary RNA engineering to develop medicines across therapeutic areas such as retinal and other ophthalmic diseases, neurological conditions, and metabolic disorders. City Therapeutics, Inc. operates within the biopharmaceutical sector, serving the broader healthcare market through research, drug development, and clinical-stage therapeutic programs rather than commercialized products. Its role in the financial market reflects exposure to the biotechnology industry, particularly the growing field of RNA-based medicine, where specialized delivery systems and precise gene silencing are central to addressing diseases that have historically been difficult to treat.

CEO Dr. Andrew C. Orth M.B.A. · 75 employees · United States · https://www.citytx.com